| Trial ID: | L3960 |
| Source ID: | NCT05327595
|
| Associated Drug: |
Ly3549492
|
| Title: |
A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: LY3549492|DRUG: Placebo|DRUG: Atorvastatin|DRUG: Midazolam
|
| Outcome Measures: |
Primary: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module, Baseline through final follow-up at approximately Day 49 | Secondary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3549492, PK: AUC of LY3549492, Day 1 predose up to Day 35|PK: Maximum Concentration (Cmax) of LY3549492, PK: Cmax of LY3549492, Day 1 predose up to Day 35|Pharmacodynamics (PD): Change from Baseline to Day 28 in Fasting Glucose, PD: Change from Baseline to Day 28 in Fasting Glucose, Baseline, Day 28|PD: Change from Baseline to Day 28 in Oral Glucose Tolerance (OGTT) 2 Hour Glucose, PD: Change from Baseline to Day 28 in OGTT 2 Hour Glucose, Baseline, Day 28
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
80
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2022-05-09
|
| Completion Date: |
2024-04-22
|
| Results First Posted: |
|
| Last Update Posted: |
2024-05-30
|
| Locations: |
Profil Institut für Stoffwechselforschung, Neuss, 41460, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT05327595
|
